Jove
Visualize
Contáctanos

Videos de Conceptos Relacionados

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
In-vitro Mutagenesis01:16

In-vitro Mutagenesis

14.6K
To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
14.6K
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

428
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
428
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Mismatch Repair01:20

Mismatch Repair

5.3K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
5.3K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Lethal toxin-equipped effector cells for the potential treatment of cancer.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Bispecific antibodies and CAR T cells targeting a TP53 mutation-associated neoantigen show discordant affinity requirements.

The Journal of clinical investigation·2026
Same author

TRBC2-targeting antibody-drug conjugates for the treatment of T cell cancers.

Nature cancer·2025
Same author

Engineering immunotoxin-equipped effector cells and evaluation in primary human immune cells.

bioRxiv : the preprint server for biology·2025
Same author

Preclinical studies show that Co-STARs combine the advantages of chimeric antigen and T cell receptors for the treatment of tumors with low antigen densities.

Science translational medicine·2024
Same author

Hydrophobic interactions dominate the recognition of a KRAS G12V neoantigen.

Nature communications·2023
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Video Experimental Relacionado

Updated: Sep 27, 2025

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.3K

Terapia guiada por mutaciones

Jacqueline Douglass1

  • 1Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, MD, USA.

Science (New York, N.Y.)
|April 7, 2022
PubMed
Resumen

Los investigadores están desarrollando nuevos anticuerpos bispecíficos para atacar con precisión las células cancerosas que expresan péptidos mutantes. Este enfoque innovador tiene como objetivo mejorar la especificidad terapéutica y la eficacia en los tratamientos oncológicos.

Área de la Ciencia:

  • En el campo de la oncología
  • La inmunoterapia
  • Biología molecular

Sus antecedentes:

  • Las células cancerosas a menudo expresan péptidos mutantes únicos que no se encuentran en los tejidos sanos.
  • Las terapias actuales pueden carecer de especificidad, lo que lleva a efectos fuera del objetivo.
  • Los anticuerpos bispecíficos ofrecen una estrategia potencial para la terapia dirigida contra el cáncer.

Objetivo del estudio:

  • Desarrollar y caracterizar anticuerpos bispecíficos diseñados para reconocer péptidos mutantes específicos.
  • Evaluar el potencial de estos anticuerpos para el tratamiento dirigido del cáncer.

Principales métodos:

  • Diseño y construcción de construcciones de anticuerpos bispecíficos.
  • Validación in vitro de la unión de anticuerpos a los péptidos mutantes objetivo.

Más Videos Relacionados

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.4K
Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

1.9K

Videos de Experimentos Relacionados

Last Updated: Sep 27, 2025

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.3K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.4K
Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

1.9K
  • Evaluación de las respuestas celulares mediadas por anticuerpos.

    • Principales resultados:

    • Generación exitosa de anticuerpos bispecíficos capaces de unirse a los péptidos mutantes seleccionados.
    • Demostración de la orientación específica de las células cancerosas que expresan estos péptidos mutantes.

    Conclusiones:

    • Los anticuerpos bispecíficos representan una plataforma prometedora para desarrollar terapias dirigidas contra el cáncer.
    • Se requiere una investigación adicional para explorar su aplicación clínica en cánceres mutantes impulsados por péptidos.